



MARKET RELEASE

17 March 2014

Bionomics Limited

TRADING HALT

The securities of Bionomics Limited (the "Company") will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of commencement of normal trading on Wednesday, 19 March 2014, or when the announcement is released to the market.

Security Code: BNO

Shannon Hong
Adviser, Listings Compliance

17 March 2014

Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney NSW 2000

Attention: Shannon Hong

Dear Shannon

Request for Trading Halt

Pursuant to Listing Rule 17.1, Bionomics Limited (ASX: BNO) (ADR: BMICY) requests a trading halt be granted by the Australian Securities Exchange with respect to its securities, commencing from the start of trading today.

The trading halt is requested pending an announcement from the Company regarding the announcement of results from its Phase II BNC105 Renal Cancer clinical trial.

Bionomics requests that the trading halt operates until an announcement is made or the commencement of trading on Wednesday 19 March 2014 (whichever occurs sooner).

Bionomics is not aware of any reason why the trading halt should not be granted.

Bionomics is not aware of any other information about which the market should be informed in relation to the trading halt.

Yours faithfully
Bionomics Limited



Melanie Young
Chief Financial Officer & Company Secretary